Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
15:39:07 EDT Mon 20 Jul 2026
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:IONS - IONIS PHARMACEUTICALS INC - https://www.ionispharma.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
IONS - Q5.753.19·53.221.153.22-1.17-2.21,039.453,05613,24954.57  54.795  53.2286.74  40.0315:23:01Jul 1515 min RT 2¢

Recent Trades - Last 10 of 13249
Time ETExPriceChangeVolume
15:23:11Q53.16-1.23100
15:23:11Q53.17-1.2225
15:23:10Q53.18-1.211
15:23:10Q53.18-1.2159
15:23:10Q53.18-1.211
15:23:10Q53.18-1.2130
15:23:10Q53.17-1.22100
15:23:10Q53.17-1.2258
15:23:10Q53.18-1.211
15:23:10Q53.17-1.22100

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-07-15 07:05U:IONSNews ReleaseIonis to hold second quarter 2026 financial results webcast
2026-07-14 09:16U:IONSNews ReleaseIonis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer's Disease
2026-07-13 07:00U:IONSNews ReleaseIonis doses first participant in Phase 1-2 ASCEND study of ION337 in Dravet syndrome
2026-07-09 02:00U:IONSNews ReleaseUpdate on CARDIO-TTRansform Phase 3 trial of eplontersen in adults with transthyretin-mediated amyloid cardiomyopathy
2026-07-06 07:00U:IONSNews ReleaseIonis completes enrollment in pivotal cohort of the Phase 3 REVEAL study evaluating obudanersen in Angelman syndrome
2026-06-25 02:59U:IONSNews ReleaseIonis announces license agreement with Recordati for zilganersen in Alexander disease (AxD) in all countries outside the U.S.
2026-06-24 14:37U:IONSNews ReleaseTRYNGOLZA(TM) (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia (sHTG)
2026-06-08 07:00U:IONSNews ReleaseIonis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors
2026-06-04 07:00U:IONSNews ReleaseIonis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congresses
2026-05-28 04:45U:IONSNews ReleaseIonis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B
2026-05-14 07:05U:IONSNews ReleaseIonis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer's disease
2026-05-04 07:05U:IONSNews ReleaseIonis to host 2026 virtual Annual Meeting of Stockholders
2026-05-01 07:05U:IONSNews ReleaseIonis to present at upcoming investor conferences
2026-04-29 07:00U:IONSNews ReleaseIonis reports first quarter 2026 financial results and highlights progress on key programs
2026-04-28 02:06U:IONSNews ReleaseIonis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis B
2026-04-21 07:00U:IONSNews ReleaseIonis presents new data from pivotal study of zilganersen in Alexander disease (AxD) at AAN 2026 Annual Meeting
2026-04-15 07:05U:IONSNews ReleaseIonis to hold first quarter 2026 financial results webcast
2026-03-23 07:00U:IONSNews ReleaseIonis announces zilganersen New Drug Application for Alexander disease (AxD) accepted by FDA for Priority Review
2026-03-09 07:00U:IONSNews ReleaseIonis announces changes to Board of Directors
2026-02-27 07:00U:IONSNews ReleaseIonis to present new data supporting DAWNZERA(TM) (donidalorsen) in hereditary angioedema at 2026 AAAAI Annual Meeting